ANAVEX LIFE SCIENCES CORP.

AVXLSEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1314052

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$43.7M	$43.7M	$33.0M	$25.2M	$25.2M
Selling, General and Administrative Expense	$12.0M	—	—	—	—
Operating Expenses	$55.8M	$55.8M	$42.0M	-$31.1M	$31.1M
Operating Income (Loss)	-$55.8M	-$55.8M	-$42.0M	-$31.1M	—
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$8.3M	$8.3M	$4.4M	$4.8M	$4.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$47.5M	-$47.5M	-$37.6M	-$26.3M	-$26.3M
Income Tax Expense (Benefit)	—	—	—	—	—
Net Income (Loss) Attributable to Parent	-$47.5M	-$47.5M	-$37.9M	-$26.3M	-$26.3M
Earnings Per Share, Basic	-$0.60	-$0.60	-$0.54	—	—
Earnings Per Share, Diluted	-$0.60	-$0.60	-$0.54	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$135.6M	$154.4M	$152.7M	$161.6M	$34.5M
Assets, Current	—	—	—	—	—
Cash and Cash Equivalents, at Carrying Value	$132.2M	$151.0M	$149.2M	$152.1M	$29.2M
Liabilities	$15.3M	$12.5M	$10.2M	$10.8M	$7.3M
Liabilities, Current	—	—	—	—	—
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$9.6M	$4.3M	$3.8M	$4.7M	$4.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$27.8M	-$27.8M	-$30.4M	-$21.3M	-$21.3M
Net Cash Provided by (Used in) Investing Activities	—	—	—	—	—
Net Cash Provided by (Used in) Financing Activities	$29.7M	$29.7M	$153.2M	$28.4M	$28.4M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)